Stock Price Movement and Market Context
On 22 Dec 2025, Shree Ganesh Remedies recorded an intraday low of Rs.418, representing a 4.05% decline during the trading session. This drop contributed to an overall day change of -1.30%, underperforming its Pharmaceuticals & Biotechnology sector by 2.52%. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained downward momentum.
In contrast, the broader market has shown resilience. The Sensex opened 216.54 points higher and further climbed 265.18 points to close at 85,411.08, a 0.57% gain. The benchmark index remains close to its 52-week high of 86,159.02, trading 0.88% below that peak. Additionally, the BSE Small Cap index gained 1.02%, leading market advances on the day.
One-Year Performance Comparison
Over the past year, Shree Ganesh Remedies has generated a return of -37.68%, significantly lagging behind the Sensex’s 9.44% gain and the BSE500’s 6.60% return. This underperformance highlights the challenges faced by the company relative to the broader market and its sector peers.
Financial Results and Profitability Trends
The company has reported negative results for three consecutive quarters. Its Profit Before Tax (PBT) for the latest quarter stood at Rs.6.02 crore, reflecting a decline of 28.76% compared to previous periods. Similarly, the Profit After Tax (PAT) for the last six months was Rs.8.41 crore, showing a reduction of 23.96%. These figures indicate a contraction in profitability over recent reporting intervals.
Return on Capital Employed (ROCE) for the half year is recorded at 16.18%, which is among the lower levels for the company. Return on Equity (ROE) stands at 13.3%, suggesting moderate returns relative to shareholder equity. The Price to Book Value ratio is 3.6, indicating the stock is valued at a premium to its book value but remains discounted compared to historical peer valuations.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Debt and Valuation Metrics
Shree Ganesh Remedies maintains a low Debt to EBITDA ratio of 0.47 times, indicating a relatively strong capacity to service its debt obligations. Despite the company’s size, domestic mutual funds hold no stake in the stock, which may reflect a cautious stance given the current financial performance and valuation.
The stock’s 52-week high was Rs.950, more than double the current price level, underscoring the extent of the decline over the past year. Profitability has also contracted, with profits falling by 28.2% during this period, aligning with the negative returns generated by the stock price.
Why settle for Shree Ganesh Remedies ? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Sector and Market Position
Operating within the Pharmaceuticals & Biotechnology industry, Shree Ganesh Remedies faces a competitive environment where many peers have maintained or improved valuations and profitability. The stock’s current valuation metrics suggest it is trading at a discount relative to its historical averages and peer group, reflecting the market’s assessment of recent financial performance.
While the broader sector and market indices have shown positive trends, Shree Ganesh Remedies’ share price has not mirrored this movement, highlighting a divergence that has persisted over the last twelve months.
Summary of Key Financial Indicators
To summarise, the company’s key financial indicators for the recent periods include:
- Profit Before Tax (latest quarter): Rs.6.02 crore, down 28.76%
- Profit After Tax (last six months): Rs.8.41 crore, down 23.96%
- Return on Capital Employed (half year): 16.18%
- Return on Equity: 13.3%
- Debt to EBITDA ratio: 0.47 times
- Price to Book Value: 3.6
- One-year stock return: -37.68%
These figures collectively illustrate the financial pressures experienced by Shree Ganesh Remedies over the past year, contributing to the stock’s decline to its current 52-week low.
Market Sentiment and Trading Patterns
Trading activity shows the stock has consistently remained below all major moving averages, a technical indication of sustained bearish momentum. This contrasts with the Sensex, which is trading above its 50-day and 200-day moving averages, signalling a bullish trend for the broader market.
The divergence between Shree Ganesh Remedies’ share price trajectory and the overall market performance highlights the specific challenges faced by the company within its sector.
Conclusion
Shree Ganesh Remedies’ fall to a 52-week low of Rs.418 reflects a combination of subdued financial results, declining profitability, and market valuation pressures. Despite a stable debt position and moderate returns on equity, the stock’s performance has lagged significantly behind the broader market and its sector peers over the past year. The current trading levels and financial metrics provide a comprehensive view of the company’s recent performance within the Pharmaceuticals & Biotechnology industry.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Claim Your Free Year →
